Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Poland.
J Hypertens. 2012 Sep;30(9):1681-9. doi: 10.1097/HJH.0b013e3283569a9c.
Biomarkers should have high sensitivity, specificity, reproducibility, be cost-effective, and provide incremental predictive or diagnostic utility over standard risk factors or tests. Despite numerous studies investigating biomarkers in heart failure (HF), there are only a few that predict HF in hypertensive patients. This article summarizes data from numerous studies concerning possible biomarkers of HF in hypertensive patients such as: serum uric acid (SUA), interleukins, monocyte chemoattractant protein one (MCP-1), cardiotrophin-1 (CT-1), carboxy-terminal propeptide of procollagen type I (PICP), type I collagen telopeptide (CITP) and N-terminal propeptide of type III procollagen (PIIINP), metalloproteinases (MMPs), B-type natriuretic peptide (BNP) and its derivatives, glycoprotein CA125 and cystatin C. Early detection of patients of increased risk of hypertensive heart disease may result in early implementation of effective preventive strategies. Therefore, there is need to identify newer biomarkers, if they can improve risk prediction, identifying patients, in which earlier or more aggressive intervention will improve clinical outcomes.
生物标志物应具有高灵敏度、特异性、重现性、成本效益，并能提供比标准风险因素或检测更具增量预测或诊断价值。尽管有许多研究探讨了心力衰竭 (HF) 中的生物标志物，但只有少数研究能预测高血压患者的 HF。本文总结了许多研究中有关高血压患者 HF 潜在生物标志物的资料，例如：血清尿酸 (SUA)、白细胞介素、单核细胞趋化蛋白 1 (MCP-1)、心营养素 1 (CT-1)、I 型胶原羧基末端前肽 (PICP)、I 型胶原 C 末端肽 (CITP) 和 III 型前胶原 N 末端肽 (PIIINP)、金属蛋白酶 (MMPs)、B 型利钠肽 (BNP) 及其衍生物、糖蛋白 CA125 和半胱氨酸蛋白酶抑制剂 C。早期发现高血压性心脏病风险增加的患者可能会导致早期实施有效的预防策略。因此，如果新的生物标志物能够改善风险预测，识别出需要更早或更积极干预才能改善临床结局的患者，那么就有必要加以确定。
